Case Report | Open Access
Yu Wang, Ruzeng Xue, "Cutaneous Metastases from Lung Adenocarcinoma", Case Reports in Dermatological Medicine, vol. 2020, Article ID 8880604, 3 pages, 2020. https://doi.org/10.1155/2020/8880604
Cutaneous Metastases from Lung Adenocarcinoma
Cutaneous metastases are unusual presenting symptoms of lung cancer. Therefore, they are prone to be misdiagnosed and missed. The report describes a case of a forty-nine-year-old female with painful zosteriform rashes showing multiple vesicle-like papules localized on the left breast for 10 days. The patient had been diagnosed as lung adenocarcinoma at the department of oncology one year ago. Skin biopsy revealed blue nodular lesions in the dermis, composed of clustered heterogeneous tumor cells with glandular formation. Immunohistochemical stains confirmed the diagnosis of metastatic lung adenocarcinoma.
Lung cancer can metastasize to almost all organs but more often invades the hilar nodes, liver, adrenal glands, bones, and brain . The incidence of lung cancer with metastases to the skin varies between 1–12% . A lung cancer metastasis is usually classified only as adenocarcinoma, squamous cell carcinoma (SCC), or undifferentiated carcinoma. Until the 1980s, SCC was reported as the most common type of lung cancer. However, adenocarcinoma has replaced SCC as the most common lung cancer subtype, especially in women and in never-smokers. Sun et al. reported that the type of adenocarcinoma was 3.4 times more frequent than that of SCC . Skin metastases can appear on any cutaneous surface, and the most common sites are the chest, abdomen, head, and neck [3, 4]. Cutaneous metastases have various manifestations, such as single papules/nodules or multiple lesions on anywhere of the skin, while other rare forms may show plaque-like lesions, erysipelas-like papules, zosteriform lesions, and scars [3, 5].
2. Case Presentation
A forty-nine-year-old nonsmoker female was admitted to our department with multiple painful papules localized on the left breast. They appeared eruptively for about 10 days and initially diagnosed as herpes zoster in another hospital. The patient had been diagnosed as lung adenocarcinoma at the department of oncology one year ago. She was given oxitinib mesylate, a targeted drug for the treatment of non-small-cell lung cancer. In addition, the patient exhibited symptom of pain, signs of weight loss, anorexia, and fatigue.
Physical examination showed zosteriform vesicle-like papules, measuring 0.5–1.0 cm on the left breast. The lesions were pink or red, firm, and tender (Figure 1). Excisional biopsy was performed revealing blue nodular lesions infiltrating in the dermis, composed of clustered heterogeneous tumor cells with glandular formation. Some tumor cells were detected within vessels or lymphatic vessels. Some cells were transparent. Mitosis was significant (Figures 2(a)–2(c)). In immunohistochemistry, tumor cells were positive for cytokeratin (CK), cytokeratin-7 (CK7), thyroid transcription factor-1 (TTF1), and EMA and negative for cytokeratin-20 (CK20), carcinoembryonic antigen (CEA), and gross cystic disease fluid protein-15 (GCDFP-15) (Figures 3(a)–3(c)). Proliferative index, as measured by Ki-67, was approximately 45–50% of tumor cells. According to the clinical and pathological features, cutaneous metastatic lung adenocarcinoma was made.
Skin metastases suggest the progression of primary cancer and portend a poor clinical prognosis. Skin metastases from lung cancer are rare. The percentage of patients with lung cancer that develops cutaneous metastases ranges from 1 to 12 percent . It is seen more often in men than in women . It does not show any specific presentation. It is often painless and less likely to be noticed, making it more difficult to be diagnosed correctly, which may delay treatment. Although described cases show that metastatic nodules are painless, our patient showed severe pain. The presence of zosteriform painful vesicle-like lesions really mimics herpes zoster clinically in our case.
The mechanisms determining the metastasis of lung cancer in skin remain unknown. Pathogenesis is suggested to be by lymphovascular invasion, with poor differentiation and upper lobe tumors increasing the risk . Usually, skin metastasis develops after initial diagnosis of the primary malignancy and late in the course of the disease. Occasionally, skin lesions that arise from lung cancer may develop before the primary tumor is recognized. In our case, skin metastases occurred during the immunotherapy. Histology shows most commonly adenocarcinoma and then squamous/small-cell followed by large-cell carcinoma . Immunohistochemical markers are useful for the identification of the primary cancer or when a shorter differential is desired. Anti-TTF is both sensitive and specific for primary adenocarcinomas, bronchioalveolar carcinomas, and small-cell carcinomas when thyroid primary is excluded . CK7+and CK20− are sensitive but not specific for primary adenocarcinomas and bronchioalveolar carcinomas. The CK7+/CK20−tumors usually include the lung, breast, endometrium, ovary, thyroid, salivary gland, and mesothelioma [8, 9].
Treatment of a single solitary skin lesion usually includes surgery alone or combined with chemotherapy, and/or radiation. If lesions are more disseminated, chemotherapy is the primary option but may elicit an inadequate response . Radiation can also be used alone and/or in combination with chemotherapy, and/or surgery. However, despite the combination of radiotherapy and chemotherapy, patients with lung cancer developing cutaneous metastases have a poor outcome. Mean survival is short, usually 5 to 6 months after diagnosis of cutaneous metastasis .
Conflicts of Interest
The authors declare they have no conflicts of interest.
This work was supported by a grant from the National Natural Science Foundation of China (81903200).
- T. W. Mollet, C. A. Garcia, and G. Koester, “Skin metastases from lung cancer,” Dermatology Online Journal, vol. 15, no. 5, 2009.
- S. Sun, J. H. Schiller, and A. F. Gazdar, “Lung cancer in never smokers-a different disease,” Nature Reviews Cancer, vol. 7, no. 10, pp. 778–790, 2007.
- S. Dreizen, H. M. Dhingra, D. F. Chiuten, T. Umsawasdi, and M. Valdivieso, “Cutaneous and subcutaneous metastases of lung cancer,” Postgraduate Medicine, vol. 80, no. 8, pp. 111–116, 1986.
- M. Khaja, D. Mundt, R. A. Dudekula et al., “Lung cancer presenting as skin metastasis of the back and hand: a case series and literature review,” Case Reports in Oncology, vol. 12, no. 2, pp. 480–487, 2019.
- W. T. McSweeney and K. Tan, “Cutaneous metastases as a presenting sign of metastatic NSCLC,” Journal of Surgical Case Reports, vol. 2019, no. 10, 2019.
- M. H. Brownstein and E. B. Helwig, “Metastatic tumors of the skin,” Cancer, vol. 29, no. 5, pp. 1298–1307, 1972.
- R. B. McGrath, S. P. Flood, and R. Casey, “Cutaneous metastases in non-small cell lung cancer,” BMJ Case Reports, vol. 2014, 2014.
- V. Jerome Marson, J. Mazieres, O. Groussard et al., “Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade,” Histopathology, vol. 45, no. 2, pp. 125–134, 2004.
- R. Koca, Y. Ustundag, E. Kargi, G. Numanoglu, and H. C. Altinyazar, “A case with widespread cutaneous metastases of unknown primary origin: grave prognostic finding in cancer,” Dermatology Online Journal, vol. 11, no. 1, p. 16, 2005.
- N. A. Babacan, S. Kilickap, S. Sene et al., “A case of multifocal skin metastases from lung cancer presenting with vasculitic-type cutaneous nodule,” Indian Journal of Dermatology, vol. 60, p. 213, 2015.
Copyright © 2020 Yu Wang and Ruzeng Xue. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.